Inhaled Ondansetron & Dyspnea
Primary Purpose
Dyspnea
Status
Completed
Phase
Early Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Ondansetron
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Dyspnea focused on measuring Ondansetron, Exercise
Eligibility Criteria
Inclusion Criteria:
- Male
- Aged 20-40 years
- FEV1 ≥80% predicted
- FEV1/FVC >70%
Exclusion Criteria:
- Current or ex-smoker
- Body Mass Index <18.5 or >30 kg/m2
- History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction.
- Taking doctor prescribed medications
- Allergy to latex
- Allergy to lidocaine or its "caine" derivatives
Sites / Locations
- Clinical Exercise & Respiratory Physiology Laboratory (CERPL) of McGill University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Inhaled Ondansetron (8 mg)
Inhaled 0.9% saline placebo
Arm Description
Single-dose inhalation of nebulized ondansetron (8 mg)
Single-dose inhalation of 0.9% saline placebo
Outcomes
Primary Outcome Measures
Sensory Intensity (Borg 0-10 scale) ratings of dyspnea at isotime
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01851993
Brief Title
Inhaled Ondansetron & Dyspnea
Official Title
Effects of Inhaled Ondansetron on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
"Dyspnea" refers to the awareness of breathing discomfort that is typically experienced during exercise in health and disease. In various participant populations, dyspnea is a predictor of disability and death; and contributes to exercise intolerance and an adverse health-related quality-of-life. It follows that alleviating dyspnea and improving exercise tolerance are among the principal goals of disease management. Nevertheless, the effective management of dyspnea and activity-limitation remains an elusive goal for many healthcare providers and current strategies aimed at reversing the underlying chronic disease are only partially successful in this regard. Thus, research aimed at identifying dyspnea-specific medications to complement existing therapies for the management of exertional symptoms is timely and clinically relevant. The purpose of this study is to test the hypothesis that single-dose inhalation of nebulized ondansetron (a serotonin 5-HT3 receptor antagonist) will improve the perception of dyspnea during strenuous exercise in health, young men. To this end, the investigators will compare the effects of inhaled 0.9% saline placebo and inhaled ondansetron (8 mg) on detailed assessments of neural respiratory drive (diaphragm EMG), ventilation, breathing pattern, dynamic operating lung volumes, contractile respiratory muscle function, cardio-metabolic function and dyspnea (sensory intensity and affective responses) during symptom-limited, high-intensity, constant-work-rate cycle exercise testing in healthy, men aged 20-40 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyspnea
Keywords
Ondansetron, Exercise
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Inhaled Ondansetron (8 mg)
Arm Type
Experimental
Arm Description
Single-dose inhalation of nebulized ondansetron (8 mg)
Arm Title
Inhaled 0.9% saline placebo
Arm Type
Placebo Comparator
Arm Description
Single-dose inhalation of 0.9% saline placebo
Intervention Type
Drug
Intervention Name(s)
Ondansetron
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
0.9% saline
Primary Outcome Measure Information:
Title
Sensory Intensity (Borg 0-10 scale) ratings of dyspnea at isotime
Time Frame
Participants will be followed until all study visits are complete, an expected average of 3 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male
Aged 20-40 years
FEV1 ≥80% predicted
FEV1/FVC >70%
Exclusion Criteria:
Current or ex-smoker
Body Mass Index <18.5 or >30 kg/m2
History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction.
Taking doctor prescribed medications
Allergy to latex
Allergy to lidocaine or its "caine" derivatives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dennis Jensen, Ph.D.
Organizational Affiliation
McGill University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Exercise & Respiratory Physiology Laboratory (CERPL) of McGill University
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2W1S4
Country
Canada
12. IPD Sharing Statement
Links:
URL
http://www.mcgill.ca/cerpl
Description
Clinical Exercise & Respiratory Physiology Laboratory (CERPL) of McGill University
Learn more about this trial
Inhaled Ondansetron & Dyspnea
We'll reach out to this number within 24 hrs